OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.69 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 17.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 20,284 shares of the biopharmaceutical company’s stock after buying an additional 2,941 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Intra-Cellular Therapies were worth $1,694,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in ITCI. M&T Bank Corp raised its position in Intra-Cellular Therapies by 2.2% in the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock worth $526,000 after purchasing an additional 138 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Intra-Cellular Therapies by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 141 shares in the last quarter. CIBC Asset Management Inc grew its stake in Intra-Cellular Therapies by 5.3% during the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 150 shares during the last quarter. Pallas Capital Advisors LLC grew its stake in Intra-Cellular Therapies by 6.4% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 192 shares during the last quarter. Finally, Arizona State Retirement System grew its stake in Intra-Cellular Therapies by 0.8% during the fourth quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company’s stock worth $2,302,000 after buying an additional 206 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock opened at $131.87 on Wednesday. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.98. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The firm’s 50 day moving average price is $131.74 and its two-hundred day moving average price is $112.79.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research note on Wednesday, May 7th. They set a “hold” rating on the stock. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Finally, Piper Sandler reissued a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Eleven research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Intra-Cellular Therapies has an average rating of “Hold” and a consensus target price of $109.70.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.